Verdict at a Glance Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss
It has not been tested against tirzepatide
These cover your weight history, medications, allergies, and goals, as well as giving your provider the context they need
Other peptides that the body makes include insulin, substance P, neuropeptide Y, ghrelin, CCK, leptin, leuteinizing hormone, thyroid-stimulating hormone, and more
Long-Term Accumulation Weekly Peak: The highest concentration reached shortly after an individual dose (13 days)
KohADe VadderFKovatcheva-DatcharyPBckhedF